Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Eli Lilly (NYSE:LLY) underwent analysis by 7 analysts ... and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Market Capitalization: Positioned above industry average, the ...

and Taltz and Olumiant for immunology. In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Eli Lilly's innovative culture and strong financial ... and Jardiance as well as immunology drug Taltz, cancer drug Verzenio, and Alzheimer's drug Kisunla hold the highest sales potential of ...

Stockpiling of drugs for chronic diseases like diabetes during the coronavirus pandemic lifted Eli Lilly’s ... as psoriasis treatment Taltz (ixekizumab). All told, Lilly’s sales rose 15% ...

Prior to working at BMS, Dr. Banerjee served as a global clinical program lead at Eli Lilly and Company on the clinical ...

Besides GLP-1 therapies, Eli Lilly's other drugs, such as Verzenio, Jardiance, and Taltz also demonstrated robust growth in 2024, highlighting the strength of its diversified drug portfolio.

To evaluate those effects for up to 52 weeks, Maksymowych and colleagues conducted a post hoc analysis of COAST-V, a phase 3 trial that assessed ixekizumab (Taltz, Eli Lilly & Co.) against ...